A Global Imatinib and Nilotinib Pregnancy Exposure Registry
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a voluntary, international, primarily prospective, observational, exposure-registry
and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six
months prior to pregnancy.